KNG1 and COVID-19: Bradykinin also contributes to this inflammatory and hyperfibrinolytic state through the release of tPA [271], implicating it in the coagulation imbalances that occur in patients with COVID-19 (hyperfibrinolysis or thromboembolism) [272].